RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use

NZ836712APending Publication Date: 2026-09-25ARROWHEAD PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ836712
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-24
Filing Date
2021-09-10
Publication Date
2026-09-25

Smart Images

  • Figure 00000263_0000
    Figure 00000263_0000
  • Figure 00000264_0000
    Figure 00000264_0000
  • Figure 00000265_0000
    Figure 00000265_0000
Patent Text Reader

Abstract

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a double homeobox 4 ( DUX4 ) gene. The DUX4 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DUX4 gene. Pharmaceutical compositions that include one or more DUX4 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DUX4 RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DUX4 gene expression and a reduction in DUX4 levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including Facioscapulohumeral Muscular Dystrophy (FSHD).
Need to check novelty before this filing date? Find Prior Art